Promising whole-cell vaccines against cryptococcosis.
cryptococcosis
immune memory
subunit vaccine
trained immunity
whole-cell vaccine
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
09
02
2023
received:
27
12
2022
accepted:
12
02
2023
medline:
4
5
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
Cryptococcosis is a mycosis caused by Cryptococcus neoformans and C. gattii species complexes. Although this infection is potentially lethal, no prophylactic vaccine is yet commercially available, and the immune memory that enables prevention is still under investigation. These pathogens have a capsule layer for immune evasion and a sophisticated mechanism to advance the infection, and it is expected that these characteristics will make it difficult to develop prophylactic vaccines and to decipher the protective immunity. The current vaccine studies are focused on subunit, mRNA, DNA, and viral vector vaccines, with whole-cell vaccines also proving successful against cryptococcal infections. Cryptococcal whole-cell vaccines have been composed of highly immunostimulating strains with low-pathogenicity that are modified by genetic recombination technology. Examples include the whole-cell vaccines H99γ, sgl1∆, fbp1∆, znf2
Identifiants
pubmed: 36786396
doi: 10.1111/1348-0421.13056
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-223Subventions
Organisme : The Japan Agency for Medical Research and Development
ID : AMED JP21ad0027002
Organisme : The Japan Agency for Medical Research and Development
ID : JP21fk0108094
Organisme : The Japan Agency for Medical Research and Development
ID : JP22fk0108135
Organisme : The Japan Agency for Medical Research and Development
ID : JP22fk0108139
Organisme : Our studies are supported by the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : KAKENHI 20K07507
Informations de copyright
© 2023 The Societies and John Wiley & Sons Australia, Ltd.
Références
Kwon-Chung KJ, Bennett JE, Wickes BL, et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. mSphere. 2017;2(1):e00357-16.
Espinel-Ingroff A, Kidd S. Current trends in the prevalence of Cryptococcus gattii in the United States and Canada. Infect Drug Resist. 2015;8:89-97.
Kohno S, Kakeya H, Izumikawa K, et al. Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. J Infect Chemother. 2015;21(1):23-30.
Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-1.
Ueno K, Yanagihara N, Shimizu K, Miyazaki Y. Vaccines and protective immune memory against cryptococcosis. Biol Pharm Bull. 2020;43(2):230-9.
Caballero Van Dyke MC, Wormley FL. A call to arms: quest for a cryptococcal vaccine. TIM. 2018;26(5):436-6.
Louria DB. Specific and non-specific immunity in experimental cryptococcosis in mice. J Exp Med. 1960;111(5):643-65.
Gadebusch HH. Specific degradation of Cryptococcus neoformans 3723 capsular polysaccharide by a microbial enzyme III. Antibody stimulation by partially decapsulated cells. J Infect Dis. 1960;107(3):406-9.
Reiss F, Alture-Werber E. Immunization of mice with a mutant of Cryptococcus neoformans. Characterization of the mutant, actively acquired resistance to experimental cryptococcosis in mice. Dermatology. 1976;152(1):16-22.
Fromtling RA, Kaplan AM, Shadomy HJ. Immunization of mice with stable, acapsular, yeast-like mutants of Cryptococcus neoformans. Med Mycol. 1983;21(2):113-9.
Fromtling RA, Blackstock R, Hall NK, Bulmer GS. Immunization of mice with an avirulent pseudohyphal form of Cryptococcus neoformans. Mycopathologia. 1979;68(3):179-81.
Hill JO, Aguirre KM. CD4+ T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J Immunol. 1994;152(5):2344-50.
Wormley FL, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun. 2007;75(3):1453-62.
Wozniak KL, Ravi S, Macias S, et al. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One. 2009;4(9):e6854.
Wozniak KL, Young ML, Wormley FL. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol. 2011;18(5):717-23.
Van Dyke MCC, Chaturvedi AK, Hardison SE, et al. Induction of broad-spectrum protective immunity against disparate Cryptococcus serotypes. Front Immunol. 2017;8:1359.
Leopold Wager CM, Hole CR, Campuzano A, et al. IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans. PLoS Pathog. 2018;14(10):e1007358.
Hole CR, Wager CML, Castro-Lopez N, et al. Induction of memory-like dendritic cell responses in vivo. Nat Commun. 2019;10(1):2955.
Rella A, Mor V, Farnoud AM, et al. Role of sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front Microbiol. 2015;6:836.
Colombo AC, Rella A, Normile T, et al. Cryptococcus neoformans glucuronoxylomannan and sterylglucoside are required for host protection in an animal vaccination model. mBio. 2019;10(2): e02909-18.
Normile TG, Rella A, Del Poeta M. Cryptococcus neoformans Δsgl1 vaccination requires either CD4+ or CD8+ T cells for complete host protection. Front Cell Infect Microbiol. 2021;11:739027.
Normile TG, Del Poeta M. Three models of vaccination strategies against cryptococcosis in immunocompromised hosts using heat-killed Cryptococcus neoformans Δsgl1. Front Immunol. 2022;13:868523.
Normile TG, Chu TH, Sheridan BS, Poeta MD. Vaccine protection by Cryptococcus neoformans Δsgl1 is mediated by γδ T cells via TLR2 signaling. Mucosal Immunol. 2022;15:1416-30.
Specht CA, Lee CK, Huang H, et al. Protection against experimental cryptococcosis following vaccination with glucan particles containing cryptococcus alkaline extracts. mBio. 2015;6(6):e01905-15.
Ueno K, Kinjo Y, Okubo Y, et al. Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii. Infect Immun. 2015;83(4):1577-86.
Ueno K, Urai M, Sadamoto S, et al. A dendritic cell-based systemic vaccine induces long-lived lung-resident memory Th17 cells and ameliorates pulmonary mycosis. Mucosal Immunol. 2019;12(1):265-76.
Zhai B, Wozniak KL, Masso-Silva J, et al. Development of protective inflammation and cell-mediated immunity against Cryptococcus neoformans after exposure to hyphal mutants. mBio. 2015;6(5):e01433-15.
Lin J, Pham T, Hipsher K, Glueck N, Fan Y, Lin X. Immunoprotection against Cryptococcosis offered by Znf2 depends on capsule and the hyphal morphology. mBio. 2022;13:e0278521.
Upadhya R, Lam WC, Maybruck B, Specht CA, Levitz SM, Lodge JK. Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans. mBio. 2016;7(3):e00547-16.
Lam WC, Upadhya R, Specht CA, et al. Chitosan biosynthesis and virulence in the human fungal pathogen Cryptococcus gattii. mSphere. 2019;4(5):875.
Upadhya R, Lam WC, Hole CR, et al. Cryptococcus neoformans Cda1 and Cda2 coordinate deacetylation of chitin during infection to control fungal virulence. Cell Surf. 2021;7:100066.
Masso-Silva J, Espinosa V, Liu T-B, Wang Y, Xue C, Rivera A. The F-box protein Fbp1 shapes the immunogenic potential of Cryptococcus neoformans. mBio. 2018;9(1):e01828-17.
Wang Y, Wang K, Masso-Silva JA, Rivera A, Xue C. A heat-killed Cryptococcus mutant strain induces host protection against multiple invasive mycoses in amurine vaccine model. mBio. 2019;10(6):647.
Hole CR, Lam WC, Upadhya R, Lodge JK. Cryptococcus neoformans chitin synthase 3 plays a critical role in dampening host inflammatory responses. mBio. 2020;11(1):e03373-19.
Esher SK, Ost KS, Kohlbrenner MA, et al. Defects in intracellular trafficking of fungal cell wall synthases lead to aberrant host immune recognition. PLoS Pathog. 2018;14(6):e1007126.
O'Meara TR, Holmer SM, Selvig K, Dietrich F, Alspaugh JA. Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. mBio. 2013;4(1):e00522-12.
Fa Z, Xu J, Yi J, et al. TNF-α-producing Cryptococcus neoformans exerts protective effects on host defenses in murine pulmonary cryptococcosis. Front Immunol. 2019;10:1725.
Rhodes JC, Wicker LS, Urba WJ. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun. 1980;29(2):494-9.
Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26(9):1105-13.
Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon- in combination with amphotericin b in the treatment of experimental cryptococcosis. J Infect Dis. 1994;170(5):1331-4.
Kawakami K, Tohyama M, Teruya K, et al. Contribution of interferon-γ in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol. 1996;13(2):123-30.
Donald PR, Lamprecht JH, Freestone M, et al. A randomised placebo-controlled trial of the efficacy of beta-sitosterol and its glucoside as adjuvants in the treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1(6):518-22.
Lee J-H, Lee JY, Park JH, et al. Immunoregulatory activity by daucosterol, a β-sitosterol glycoside, induces protective Th1 immune response against disseminated Candidiasis in mice. Vaccine. 2007;25(19):3834-40.
Parra C, González JM, Castañeda E, Fiorentino S. Producción de anticuerpos IgG1 anti-glucuronoxilomanana en ratones resistentes a la criptococosis. Biomédica. 2005;25(1):110-9.
Pereira de Sa N, Taouil A, Kim J, et al. Structure and inhibition of Cryptococcus neoformans sterylglucosidase to develop antifungal agents. Nat Commun. 2021;12(1):5885.
Chang YC, Kwon-Chung KJ, Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994;14(7):4912-9.
Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001;166(7):4620-6.
O'Meara TR, Alspaugh JA. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev. 2012;25(3):387-408.
Bulmer GS, Sans MD, Gunn CM. Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol. 1967;94(5):1475-9.
Ueno K, Otani Y, Yanagihara N, et al. Cryptococcus gattii alters immunostimulatory potential in response to the environment. PLoS One. 2019;14(8):e0220989.
Ueno K, Otani Y, Yanagihara N, et al. Cryptococcus gattii evades CD11b-mediated fungal recognition by coating itself with capsular polysaccharides. Eur J Immunol. 2021;51(9):2281-95.
Guo C, Chen M, Fa Z, et al. Acapsular Cryptococcus neoformans activates the NLRP3 inflammasome. Microb Infect. 2014;16(10):845-54.
Frases S, Nimrichter L, Viana NB, Nakouzi A, Casadevall A. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryotic Cell. 2008;7(2):319-27.
Heitman J, Kozel TR, Kwon-Chung KJ, John R, Perfect AC. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, editors. Cryptococcus: from human pathogen to model yeast. Washington, DC, USA: ASM Press; 2010. https://doi.org/10.1128/9781555816858
Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J. Sexual cycle of Cryptococcus neoformans var. Grubii and virulence of congenic a and α isolates. Infect Immun. 2003;71(9):4831-41.
Baker LG, Specht CA, Lodge JK. Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans. Eukaryotic Cell. 2011;10(9):1264-8.
Lin X, Jackson JC, Feretzaki M, Xue C, Heitman J. Transcription factors Mat2 and Znf2 operate cellular circuits orchestrating opposite- and same-sex mating in Cryptococcus neoformans. PLoS Genet. 2010;6(5):e1000953.
Wang L, Zhai B, Lin X. The link between morphotype transition and virulence in Cryptococcus neoformans. PLoS Pathog. 2012;8(6):e1002765.
Baker LG, Specht CA, Donlin MJ, Lodge JK. Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryotic Cell. 2007;6(5):855-67.
Liu T-B, Wang Y, Stukes S, Chen Q, Casadevall A, Xue C. The F-box protein Fbp1 regulates sexual reproduction and virulence in Cryptococcus neoformans. Eukaryotic Cell. 2011;10(6):791-802.
Liu T-B, Xue C. Fbp1-mediated ubiquitin-proteasome pathway controls Cryptococcus neoformans virulence by regulating fungal intracellular growth in macrophages. Infect Immun. 2014;82(2):557-68.
Han L-T, Wu Y-J, Liu T-B. The F-box protein Fbp1 regulates virulence of Cryptococcus neoformans through the putative zinc-binding protein Zbp1. Front Cell Infect Microbiol. 2021;11:794661.
Specht CA, Lee CK, Huang H, et al. Vaccination with recombinant cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and cryptococcal species. mBio. 2017;8(6):e01872-17.
Hester MM, Lee CK, Abraham A, et al. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2020;38(3):620-6.
Specht CA, Homan EJ, Lee CK, et al. Protection of mice against experimental cryptococcosis by synthesized peptides delivered in glucan particles. mBio. 2022;13:e0336721.
Hester MM, Oliveira LVN, Wang R, et al. Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis. Front Immunol. 2022;13:1015586.
Devi S. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine. 1996;14(9):841-4.
Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol. 2001;166(2):1087-96.
Biondo C, Beninati C, Bombaci M, et al. Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans. Infect Immun. 2003;71(9):5412-7.
Biondo C, Beninati C, Delfino D, et al. Identification and cloning of a cryptococcal deacetylase that produces protective immune responses. Infect Immun. 2002;70(5):2383-91.